A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Inclusion Criteria:

• Has signs/symptoms of moderate to severe UC for at least 3 months prior to Screening

• Has evidence of UC extending at least 15 cm from the anal verge

• Demonstrated an inadequate response, loss of response, or intolerance to at leastone of the following treatments: Oral aminosalicylates (e.g., mesalamine,sulfasalazine, olsalazine, or balsalazide), corticosteroids, immunosuppressants (e.g., azathioprine, 6-mercaptopurine, or methotrexate), advanced therapies for UC (e.g., biologic agents, Janus kinase [JAK] antagonists, or sphingosine-1-phosphate [S1P] receptor agonists)

• Subject has no prior exposure to approved or investigational anti-integrin therapies

• Agrees to abide by the study guidelines and requirements

• Capable of giving signed informed consent

Exclusion Criteria:

• Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis,radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn'sdisease

• Has positive findings on a subjective neurological screening questionnaire

• Has a concurrent, clinically significant, serious, unstable comorbidity

• Previous treatment with vedolizumab or other licensed or investigational integrininhibitors

• Participation in any other interventional study or received any investigationaltherapy within 30 days

• Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with asimilar mechanism to MORF-057

• Unable to attend study visits or comply with study procedures